Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer

Annals of Oncology

Volumn 24, Issue 5, 2013, Pages 1225-1231

  Lee, J S ^a   Park, S ^a   Park, J M ^a   Cho, J H ^a   Kim, S I ^a   Park, B W ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Breast cancer; CA 15 3; CEA; Prognostic factor; Tumor marker

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AXILLARY LYMPH NODE; AXILLARY LYMPH NODE METASTASIS; BLOOD LEVEL; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; MUCIN-1; PREOPERATIVE PERIOD; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84877152314     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds604     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Jung KW, Park S, Kong HJ et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat 2012; 44: 11-24.
3. Lonning PE. Breast cancer prognostication and prediction: are we making progress? Ann Oncol 2007; 18: viii3-viii7.
4. Elston CW, Ellis IO, Pinder SE. Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol 1999; 31: 209-223.
5. Molina R, Auge JM, Farrus B et al. Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. Clin Chem 2010; 56: 1148-1157.
6. Sandri MT, Salvatici M, Botteri E et al. Prognostic role of CA15.3 in 7942 patients with operable breast cancer. Breast Cancer Res Treat 2012; 132: 317-326.
7. Uehara M, Kinoshita T, Hojo T et al. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol 2008; 13: 447-451.
8. Maric P, Ozretic P, Levanat S et al. Tumor markers in breast cancer-evaluation of their clinical usefulness. Coll Antropol 2011; 35: 241-247.
9. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25: 5287-5312.
10. Duffy MJ. CA 15-3 and related mucins as circulating markers in breast cancer. Ann Clin Biochem 1999; 36: 579-586.
11. Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000; 26: 91-102.
12. Nicolini A, Carpi A. Postoperative follow-up of breast cancer patients: overview and progress in the use of tumor markers. Tumour Biol 2000; 21: 235-248.
13. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value?. Clin Chem 2006; 52: 345-351.
14. Park BW, Oh JW, Kim JH et al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 2008; 19: 675-681.
15. Jung YS, Na KY, Kim KS et al. Nation-wide Korean breast cancer data from 2008 using the breast cancer registration program. J Breast Cancer 2011; 14: 229-236.
16. Gion M, Boracchi P, Dittadi R et al. Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 2002; 38: 1181-1188.
17. Tampellini M, Berruti A, Gerbino A et al. Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 1997; 75: 698-702.
18. Molina R, Barak V, van Dalen A et al. Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol 2005; 26: 281-293.
19. Yerushalmi R, Tyldesley S, Kennecke H et al. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol 2012; 23: 338-345.
20. Molina R, Auge JM, Escudero JM et al. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumour Biol 2010; 31: 171-180.
21. Canizares F, Sola J, Perez M et al. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumour Biol 2001; 22: 273-281.
22. Gasparini G, Toi M, Gion M et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89: 139-147.
23. Shering SG, Sherry F, McDermott EW et al. Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma. Cancer 1998; 83: 2521-2527.
24. Ebeling FG, Stieber P, Untch M et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002; 86: 1217-1222.
25. Molina R, Filella X, Alicarte J et al. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. Anticancer Res 2003; 23: 1035-1041.
26. Duffy MJ, Duggan C, Keane R et al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 2004; 50: 559-563.
27. Nicolini A, Carpi A, Michelassi C et al. 'Tumour marker guided' salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. Biomed Pharmacother 2003; 57: 452-459.